ORF Biologics, Inc. Launches High-Quality CHO-K1 and HEK293 Cells with Optimized Growth Media
ORF Biologics, Inc. Launches High-Quality CHO-K1 and HEK293 Cells with Optimized Growth Media Tiffin, Iowa — [May 12, 2025] – ORF Biologics, Inc., Iowa’s leading provider of cells, growth factors, biotechnology tools, and reagents, proudly announces the immediate availability of standard CHO-K1 and HEK293 cell lines, accompanied by custom-matched growth media designed for optimal performance in both research and production environments. These two cell lines—Chinese Hamster Ovary (CHO-K1) and Human Embryonic Kidney 293 (HEK293)—are widely regarded as foundational systems in the biopharmaceutical industry, serving as bulwarks in recombinant protein and monoclonal antibody production. Now, researchers and manufacturers can access them from ORF Biologics with the assurance of excellent quality control, fair pricing, and responsive technical support. “CHO and HEK cells are the backbone of modern biologics,” said Anant Kamath, CEO of ORF Biologics, Inc. “We’re thrilled to make these high-performance lines available to the biotech community, especially at a time when reliable access and service have never been more important. Our goal is simple: make powerful, dependable cell systems available to anyone doing important work in this space—without the usual markups or delays.” Reliable Tools for Critical Work Both CHO-K1 and HEK293 cells offered by ORF Biologics are authenticated, high-viability stocks, maintained under rigorous standards and shipped with detailed protocols. The growth media, formulated specifically to complement each cell type, supports robust cell health, rapid adaptation, and reproducible performance across R&D and early production settings.These offerings are ideal for: Transient and stable transfection workflows Recombinant protein and antibody production Biological assay development High-throughput screening and testing In-house testing has demonstrated superlative doubling times, minimal adaptation periods, and high expression efficiency using the company’s media kits, which are available in standard and animal-origin-free formats. A Commitment to Service and Expansion “Every product we release is backed by technical expertise and personal support,” added Kamath. “We know what it’s like to need quick answers and dependable tools. That’s the standard we hold ourselves to.” ORF Biologics encourages researchers, CDMOs, and academic labs to inquire about bulk pricing, distributor partnerships, and integration into larger workflows. This launch also marks the beginning of a broader initiative: a streamlined, high-impact product line tailored to protein production, assay development, and therapeutic R&D. “Stay tuned,” Kamath added. “We’re just getting started. Our next wave of products is right around the corner.” About ORF Biologics, Inc. Based in Tiffin, Iowa, ORF Biologics, Inc. is Iowa’s leading provider of cells, growth factors, biotechnology tools, and reagents. With decades of combined experience, deep technical know-how, and a passion for making biology work better, ORF Biologics is building a new kind of biotech resource: agile, affordable, and uncompromising on quality.Media Contact:Anant Kamath, CEOORF Biologics, Inc.1110 Tall Grass Avenue,Tiffin, Iowa 52340(319) 992-0001contact@orfbiologics.com
ORF Biologics, Inc. Announces Cutting-Edge Solutions for Biologics Design and Manufacturing
ORF Biologics, Inc. Announces Cutting-Edge Solutions for Biologics Design and Manufacturing Tiffin, Iowa — [February 27, 2025] – ORF Biologics, a leading biotechnology company based in Tiffin, Iowa, is proud to announce its innovative approach to the design and manufacturing of both standard and custom biologics, including peptides, proteins, and antibodies. Under the leadership of CEO Anant Kamath, a seasoned industry expert with over 35 years of experience, ORF Biologics is positioned at the forefront of biopharmaceutical development, providing high-quality solutions that advance the future of medicine. Founded with the mission to support pharmaceutical and biotechnology companies in their quest for next-generation therapeutics and research solutions, ORF Biologics offers a comprehensive suite of products and services. From early-stage discovery to large-scale production, the company specializes in tailoring biologics for a wide range of applications, including drug development, diagnostics, and personalized medicine. “Biologics play a pivotal role in transforming healthcare, and ORF Biologics is committed to supporting the industry’s growth by delivering custom, scalable, and reliable solutions,” said Kamath. “With our intellectual property, cutting-edge technology and deep expertise, we are proud to collaborate with our clients to bring novel therapies and research tools to the market.” ORF Biologics’ team of scientists and strategic partners employ state-of-the-art platforms to ensure the highest standards of purity, yield, and stability for every biologic they produce. The company is dedicated to offering flexible solutions for both small-scale and large-scale projects, meeting the unique needs of clients in a rapidly evolving market. “Our experience and commitment to quality set us apart. Whether it’s a peptide, protein, or antibody, we strive to deliver biologics that exceed client expectations while supporting their R&D, clinical, and commercial objectives,” Kamath added. With an increasing demand for biologics in the treatment of a variety of diseases, ORF Biologics remains a trusted partner to pharmaceutical companies, universities, and research institutions across the globe. The company continues to innovate, ensuring it remains a leading force in the biologics manufacturing sector. For more information about ORF Biologics and its services, visit orfbiologics.com or contact: Anant Kamath, CEOORF Biologics, Inc.Phone: 319-992-0001Email: contact@orfbiologics.comWebsite: orfbiologics.com
